Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2005

View Archived Issues

Isotechnika sees progress on multiple fronts

MSA proves to be beneficial for the treatment of lymphomas

Vildagliptin safely lowers HbA1c levels in patients with type 2 diabetes

Savient terminates Prosaptide development efforts

InterMune sells oritavancin rights to Targanta Therapeutics

Enrollment closes in PRECISE trial of cintredekin besudotox

Animal study begins for Acusolin for cataracts

ChimeriVax-West Nile vaccine enters phase II

Novartis seeks Japanese approval for Glivec in Ph+ ALL

Wyeth and Progenics collaborate on development of methylnaltrexone

Able Laboratories sells assets to Sun Pharmaceutical Industries

Synta outlines development priorities in 2006

Positive preliminary results from study of TRANSDUR-Sufentanil patch

Recent Pfizer patent discloses new anxiolytics

New beta-adrenoceptor antagonists for eye disorders reported by Othera

Novel therapeutic agents for respiratory disorders claimed in recent patents

Results of a phase III trial evaluating human papillomavirus vaccination with Gardasil

NDA submitted for protease inhibitor TMC-114

Revlimid receives FDA approval

Insights into Cdk1 inhibition and mitotic timing

Ranolazine improves exercise ability in diabetic angina patients

Benefit of eculizumab in paroxysmal nocturnal hemoglobinuria seen at 3 years

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...